Peoples Bank OH Sells 100 Shares of Danaher Co. (NYSE:DHR)

Peoples Bank OH decreased its stake in Danaher Co. (NYSE:DHR) by 8.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,035 shares of the conglomerate’s stock after selling 100 shares during the period. Peoples Bank OH’s holdings in Danaher were worth $288,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Tsfg LLC increased its holdings in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Danaher during the 2nd quarter valued at $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher during the 1st quarter valued at $30,000. Finally, MFA Wealth Advisors LLC bought a new position in shares of Danaher during the 2nd quarter valued at $51,000. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on DHR. Royal Bank of Canada reduced their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Bank of America increased their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Barclays dropped their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, TD Cowen increased their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Trading Down 3.2 %

NYSE:DHR opened at $247.88 on Friday. The company has a 50-day moving average price of $270.43 and a 200-day moving average price of $260.43. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a market cap of $183.60 billion, a price-to-earnings ratio of 42.01, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the company posted $2.02 EPS. Danaher’s revenue was up 3.1% on a year-over-year basis. Equities analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,059 shares of company stock valued at $8,400,897 in the last three months. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.